Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)

Pfiz­er's mi­graine nasal spray from Bio­haven notch­es ap­proval

Pfiz­er’s nabbed its first ap­proval out of its Bio­haven ac­qui­si­tion with a nod for mi­graine spray Za­vzpret on Fri­day. The FDA ap­proval al­so marks a first in­tranasal de­liv­ery method among the new­er class of cal­ci­tonin gene-re­lat­ed pep­tide (CGRP) re­cep­tor an­tag­o­nists in mi­graine treat­ments.

Pfiz­er picked up za­veg­epant in its $11.6 bil­lion ac­qui­si­tion of Bio­haven, which al­so in­clud­ed Nurtec ODT and a pre­clin­i­cal port­fo­lio of CGRP as­sets, fi­nal­ized in Oc­to­ber. Bio­haven, or New Bio­haven, was spun out as a sep­a­rate com­pa­ny now de­vel­op­ing the re­main­ing non-CGRP as­sets, keep­ing the $BHVN tick­er and con­tin­u­ing to be led by CEO Vlad Coric.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.